肺鳞癌靶向治疗研究现状

With the research of driver mutations, targeted therapy for lung cancer has made a great progress. Compared with lung adenocarcinoma, treatment of squamous cell lung cancer (SCC) has been far behind. While targeted therapies have improved outcomes for patients with lung adenocarcinoma, such as EGFR-...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015175/
https://www.ncbi.nlm.nih.gov/pubmed/24113011
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.11
_version_ 1783334351148154880
collection PubMed
description With the research of driver mutations, targeted therapy for lung cancer has made a great progress. Compared with lung adenocarcinoma, treatment of squamous cell lung cancer (SCC) has been far behind. While targeted therapies have improved outcomes for patients with lung adenocarcinoma, such as EGFR-TKIs, EML4-ALK inhibitors, molecularly targeted drugs are poorly active for SCC. SCC currently lacks therapeutically exploitable genetic alterations. These observations emphasize the need for new driver mutations and "druggable" targets in SCC patients. Combining with the research in recent years, this review will discuss the research status in targeted therapy for SCC.
format Online
Article
Text
id pubmed-6015175
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60151752018-07-06 肺鳞癌靶向治疗研究现状 Zhongguo Fei Ai Za Zhi 综述 With the research of driver mutations, targeted therapy for lung cancer has made a great progress. Compared with lung adenocarcinoma, treatment of squamous cell lung cancer (SCC) has been far behind. While targeted therapies have improved outcomes for patients with lung adenocarcinoma, such as EGFR-TKIs, EML4-ALK inhibitors, molecularly targeted drugs are poorly active for SCC. SCC currently lacks therapeutically exploitable genetic alterations. These observations emphasize the need for new driver mutations and "druggable" targets in SCC patients. Combining with the research in recent years, this review will discuss the research status in targeted therapy for SCC. 中国肺癌杂志编辑部 2013-10-20 /pmc/articles/PMC6015175/ /pubmed/24113011 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.11 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
肺鳞癌靶向治疗研究现状
title 肺鳞癌靶向治疗研究现状
title_full 肺鳞癌靶向治疗研究现状
title_fullStr 肺鳞癌靶向治疗研究现状
title_full_unstemmed 肺鳞癌靶向治疗研究现状
title_short 肺鳞癌靶向治疗研究现状
title_sort 肺鳞癌靶向治疗研究现状
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015175/
https://www.ncbi.nlm.nih.gov/pubmed/24113011
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.11

Ejemplares similares